| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.03 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.03 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |